Citations 731
Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
Gangat, Naseema , Begna, Kebede H. , Al‐Kali, Aref , Litzow, Mark R. , Pardanani, Animesh , Tefferi, Ayalew , Hogan, William J.
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3945-3946
PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
Zuckerman, Tsila , Metheny, Leland , Litzow, Mark R. , Tamari, Roni , Sheleg, Michal, Rothenstein, Daniel, Halevy, Nitsan, Rowe, Jacob M. , Lazarus, Hillard M. , McGuirk, Joseph P. , Piñeiro, Luis Darío , Rowley, Scott D , Avni, Batia Ronit
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 10447-10448
Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)
Shallis, Rory M. , Winer, Eric S. , Doukas, Peter H., Geramita, Emily , Agarwal, Sonal , Merl, Man Yee, Im, Annie , Litzow, Mark R. , Weiss, Julian J , Badar, Talha , Swaroop, Alok , Doukas, Peter, Le, Henry, Abaza, Yasmin , Podoltsev, Nikolai
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8921-8922
Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
Winer, Eric S. , Shallis, Rory M. , Stahl, Maximilian , Oh, Timothy S. , Ma, Karen , Litzow, Mark R. , Bradshaw, Danielle , Stone, Richard M. , Flamand, Yael , Stempel, Jessica M. , Goldberg, Aaron D. , Patel, Anand , DuVall, Adam , Abaza, Yasmin , Ma, Karen, Badar, Talha , Kota, Vamsi , Raman, Hari S. , Luskin, Marlise R , DeAngelo, Daniel J.
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6285-6287
Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Shallis, Rory M. , Stahl, Maximilian , Correia, Guillerhme Sacchi De Camargo, Palmisiano, Neil , Bradshaw, Danielle , Dinner, Shira, Litzow, Mark R. , Badar, Talha , Atallah, Ehab , Saliba, Antoine N. , Bewersdorf, Jan Philipp , Patel, Anand , Abaza, Yasmin , Murthy, Guru Subramanian Guru , DuVall, Adam , Burkart, Madelyn , Kota, Vamsi , Goldberg, Aaron D.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6058-6060
Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
Little, Richard F. , Ansher, Sherry S., Gore, Steven D. , Harris, Lyndsay N. , Langan, Erin , Luger, Selina M. , Michaelis, Laura C. , Odenike, Olatoyosi , Radich, Jerald P. , Ramineni, Bhanu, Stiff, Patrick J. , Stone, Richard M. , Worthington, Katherine H, Zhang, Jianqiao , Litzow, Mark R. , Othus, Megan , Assouline, Sarit E. , Atallah, Ehab , Lindsley, R Coleman , Freidlin, Boris , Hourigan, Christopher S. , Ivy, S. Percy , Jiwani, Shahanawaz S. , Patton, David R. , Perales, Miguel‐Angel , Ramineni, Bhanumati , Salk, Jesse J. , Stock, Wendy , Uy, Geoffrey L. , Williams, P. Mickey, Wood, Brent L. , Yee, Laura M , Zeidan, Amer M. , Erba, Harry Paul
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9057-9060
Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
Gangat, Naseema , Ilyas, Rimal, Begna, Kebede H. , Al‐Kali, Aref , Patnaik, Mrinal M. , Litzow, Mark R. , Mangaonkar, Abhishek A. , Elliott, Michelle A. , Foran, James M. , Palmer, Jeanne , Hanson, Curtis A. , Pardanani, Animesh , Tefferi, Ayalew , McCullough, Kristen , Hogan, William J. , Alkhateeb, Hassan B. , Shah, Meera , Badar, Talha
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 9675-9676
Clinical and Genetic Characteristics of STAG2 Mutations in Myeloid Neoplasms
Katamesh, Bahga , Nanaa, Ahmad , He, Rong , Viswanatha, David S., Nguyen, Phuong L., Bessonen, Kurt, Gangat, Naseema , Begna, Kebede H. , Mangaonkar, Abhishek A. , Patnaik, Mrinal M. , Tefferi, Ayalew , Litzow, Mark R. , Foran, James M. , Al‐Kali, Aref , Greipp, Patricia T. , Hogan, William J. , Shah, Meera , Yi, Cecilia Arana , Badar, Talha , Alkhateeb, Hassan B.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 12353-12354
Comparison of Allogeneic Hematopoietic Cell Transplantation Outcomes from Younger Matched Unrelated Donor Versus Older Sibling Donor for Acute Myeloid Leukemia
Estrada‐Merly, Noel, Zhang, Mei‐Jie , Bredeson, Christopher , Litzow, Mark R. , Saber, Wael , Abid, Muhammad Bilal , Chen, Karen , Allan, David , Sabloff, Mitchell , Kebriaei, Partow
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 909-910
Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study
Geramita, Emily , Bastacky, Melissa, Cohen, Jessica B, Shallis, Rory M. , Litzow, Mark R. , Im, Annie , Wang, Hong , Bastacky, Melissa L. , Badar, Talha
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6187-6188